



**State of Louisiana**  
Louisiana Department of Health  
Bureau of Health Services Financing

**MEMORANDUM**

**DATE:** November 16, 2017

**TO:** All Louisiana Medicaid Fee for Service (FFS) Providers

**FROM:** Jen Steele, Medicaid Director

**SUBJECT:** Fee for Service (FFS) Point of Sale (POS) edits for buprenorphine implant kit (Probuphine®)

Effective November 29, 2017, the Louisiana Department of Health (LDH) Pharmacy Program in conjunction with the Louisiana Medicaid Drug Utilization Review (DUR) Board will implement Point of Sale (POS) edits for buprenorphine implant kit (Probuphine®) used in the treatment of opioid dependence. These edits will align with previous edits on buprenorphine containing products in FFS. Prescriptions for buprenorphine implant kit (Probuphine®) will be reimbursed only when the following criteria are met:

**Prescriber Requirements:**

- The prescriber is a physician.
- The prescriber has an XDEA number.
- The prescriber is licensed to prescribe buprenorphine implant kit (Probuphine®) and has provided a copy of his/her current Controlled Substance Registration Certificate indicating XDEA number and a copy of a Provider Enrollment File Update Form to Provider Enrollment.
- Only original prescriptions are covered with no allowances for refills.

**Age Requirements:**

- The patient must be 16 years of age or older.

Pharmacy claims for buprenorphine implant kit (Probuphine®) will deny when the recipient is less than 16 years old, with:

**NCPDP reject code 60** (Product/Service Not Covered for Patient Age) mapped to  
**EOB code 234** (P/F Age Restriction)

**ICD-10-CM Diagnosis Code Requirements**

Prescriptions for buprenorphine agents require an appropriate diagnosis code documented on the hard copy prescription after written or verbal consultation with the physician. The diagnosis code is required for the claim submission.

ICD-10-CM Diagnosis Code(s)	Description
F11.2*	Opioid Type Dependence

\* - any number or letter or combination of UP TO FOUR numbers and letters of an assigned ICD-10-CM diagnosis code

Claims submitted without a diagnosis code at POS will deny with:

**NCPDP reject code 39** (Missing or Invalid diagnosis code) mapped to  
**EOB code 575** (Missing or Invalid diagnosis code)

**Quantity Limits:**

Pharmacy claims for buprenorphine implant kit (Probuphine®) will deny when greater than 2 implant kits over 720 rolling days have been prescribed with the following:

**NCPDP reject code 76** (Quantity and/or days supply exceeds program maximum)  
mapped to  
**EOB Code 457** (Quantity and/or days supply exceeds program maximum)

**Concurrent Opioid Analgesic and/or Benzodiazepine Prescriptions with buprenorphine implant kit (Probuphine®):**

When a patient has an active prescription for any opioid analgesic (including buprenorphine) written by the same prescriber, the incoming buprenorphine prescription will deny as therapeutic duplication. The pharmacist will have to contact the physician for his/her authorization to assure the physician wants concurrent therapy before filling the incoming buprenorphine prescription and override the denial edit.

Concurrent opioid analgesic and/or benzodiazepine prescriptions written by a different prescriber for patients on buprenorphine will deny. **There are no provisions for overrides.**

Incoming prescriptions for buprenorphine agents will deny when there is an active prescription for buprenorphine agents on the recipient's file. **There are no provisions for overrides.**

Your continued cooperation and support of the Louisiana Medicaid Program efforts to coordinate care and improve health are greatly appreciated.

If you have questions about the contents of this memo, you may contact the Pharmacy Help Desk at (800) 437-9101 or refer to [www.lamedicaid.com](http://www.lamedicaid.com).

JS/MBW/BMW

c: Healthy Louisiana Plans  
Melwyn B. Wendt  
Molina